Navigation Links
InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Date:3/11/2009

LOS ALTOS, Calif., March 11 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on diabetes, metabolism and obesity, today announced it has completed enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD selective modulator of PPAR gamma (SPPARM) for the treatment of Type 2 diabetes (T2DM). INT131-007 is a 24 week, high dose active comparator (45mg Actos(R)) and placebo controlled study of INT131 at four doses in poorly controlled Type 2 diabetics.

"INT131-007 is an important study designed specifically to extend the encouraging findings from our Phase 2a study and demonstrate the unique properties of INT131, a potent insulin sensitizer, in patients with inadequately controlled type 2 diabetes mellitus (T2DM), said Alex DePaoli, M.D. InteKrin's Chief Medical Officer. "This Phase 2b study will provide critical efficacy, safety, and tolerability data to allow differentiation of INT131 from Actos(R) and inform dose selection for the Phase 3 program".

"InteKrin is very pleased to achieve this critical development milestone for INT131," remarked InteKrin's President and CEO, Denny Lanfear. "We anticipate having results from INT131-007 in the second half of this year concurrent with completion of all nonclinical and CMC efforts, enabling initiation of the INT131 Phase 3 program in 1H2010."

INT131 is a selective PPAR gamma modulator which has consistently demonstrated the separation of the powerful PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects. INT131 is well positioned to fulfill the unmet medical need for patients requiring safe treatment of insulin resistance, a key etiological feature in the onset and subsequent progression of T2DM, which remains inadequately addressed by current therapies.

About InteKrin (www.InteKrin.com):

InteKrin Therapeu
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  BioElectronics Corporation (OTC Pink: BIEL), maker of ... Andrew J. Whelan , President will be interviewed ... Business" at 9am EDT on Wednesday, August 5 th ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. ... the company,s flagship product, ActiPatch Therapy, is achieving in ...
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Array BioPharma ... for the fourth quarter and full year of ... Ron Squarer, Chief Executive Officer of Array, noted, ... Phase 3, are on track for regulatory submissions ... in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further ...
(Date:8/3/2015)... Aug. 3, 2015  Celsion Corporation (NASDAQ: ... host a conference call to discuss its second ... on its development programs for ThermoDox®, its proprietary ... acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy ... Monday, August 10, 2015. To participate in the ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... Medical Imaging of Fredericksburg is one of ...  Best of 2011 Radiology Facilities issue, a ... In an article titled "Small Town ... Imaging of Fredericksburg, a partnership between Mary Washington ...
... Inc., a biotechnology company developing orally-available antiviral therapeutics, ... for CMX001 in a late-breaker presentation at the ... Chemotherapy (ICAAC, Chicago – September 17-20).   ... Diseases Service at Memorial Sloan-Kettering Cancer Center and ...
Cached Medicine Technology:Medical Imaging of Fredericksburg Highlighted in Imaging Economics' Best of 2011 Radiology Facilities Issue 2Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting 2Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting 3
(Date:8/3/2015)... Salt Lake City, UT (PRWEB) , ... August 03, 2015 , ... ... announced the release of the T500 cable , a Bluetooth Code Reader accessory ... mobile devices, including iOS products. The T500 helps enable a variety of barcode ...
(Date:8/3/2015)... ... August 03, 2015 , ... They know every second counts. And when it ... offers some of the best care in the nation. For the past two months, ... average blood clot removal time in the country. During the months of June and ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
Breaking Medicine News(10 mins):Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2
... published in an upcoming issue of the World Health Organisation ... sensitive issue of border control, and the need for coherent ... flu pandemic . The report comes after the recent ... A (HN51) in Northern Sumatra: although the outbreak was contained ...
... Pharma US, Inc. today,announced results of an ... a prompt and sustained (over the 4-day,treatment ... among,hospitalized patients with euvolemic and hypervolemic hyponatremia ... correction. The study results were presented,during the ...
... All Iowa ... Communities, ... the Iowa State Police Association, the Partnership for a,Drug-Free America, along ... outreach program designed to,raise awareness and reduce demand for the highly ...
... pressure, damages cells , WEDNESDAY, Oct. 10 (HealthDay News) ... kidney disease in rats by raising their blood pressure ... report. , Previous studies in workers have found an ... (hardening of the arteries), kidney disease and gout. , ...
... smooth muscle tumors (SMTs, including leiomyoma and leiomyosarcoma) ... originate from a muscular layer of the gastrointestinal ... stomach, small intestine, and colon. SMTs are difficult ... and complete surgical resection is still considered to ...
... Vaccine Congress: A first-in-man trial of a live Listeria ... News). The Phase I/II trial was testing Lovaxin C ... developed by Advaxis as an immunotherapy that is intended ... papilloma virus (HPV), including cervical cancer and head and ...
Cached Medicine News:Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia 2Health News:Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia 3Health News:Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia 4Health News:Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia 5Health News:Partnership for a Drug-Free America and Council Bluffs Police Department Introduce Methamphetamine Prevention Program to Iowa Law Enforcement 2Health News:Partnership for a Drug-Free America and Council Bluffs Police Department Introduce Methamphetamine Prevention Program to Iowa Law Enforcement 3Health News:Advaxis, Inc. phase I/II results of lovaxin C in cervical cancer study released 2
... The ESR-100 is an automated 100-position ESR ... 50 samples daily. The instrument accurately and ... in 1.2ml or 2.0ml ESR-Vacuum Tubes. Results ... Westergren Method) and are available in 30 ...
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
... Qwik-Let® Premier is our top-of-the-line ... the attributes of the Qwik-Let® ... patented Lan-X feature. The Lan-X ... and protection in the removal ...
... The new Finnpipette Focus from Thermo ... with uncompromising performance. Advanced features such ... .01ul fine volume adjustment on microvolumes help ... in single channel pipettes. The new interchangeable ...
Medicine Products: